Retrospective Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Nov 16, 2019; 11(11): 523-530
Published online Nov 16, 2019. doi: 10.4253/wjge.v11.i11.523
Evaluating the risk of adverse events with interventional endoscopic retrograde cholangiopancreatography and endoscopic ultrasound procedures in cirrhotic patients
Timothy Yoo, Raisa Epistola, Jordan Epistola, Lawrence Ku, Michael W Fleischman, Sofiya Reicher, Viktor E Eysselein, Linda A Hou
Timothy Yoo, Raisa Epistola, Lawrence Ku, Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, CA 90509, United States
Jordan Epistola, Department of Psychology, Social, Decision, and Organizational Sciences Program, University of Maryland, College Park, MD 20742, United States
Michael W Fleischman, Sofiya Reicher, Viktor E Eysselein, Linda A Hou, Department of Internal Medicine, Division of Gastroenterology, Harbor-UCLA Medical Center, Torrance, CA 90509, United States
Author contributions: Yoo T, Epistola R and Ku L assisted in data gathering; Yoo T contributed to data analysis; all authors contributed to writing/editing the paper; Epistola J performed the statistical analysis; Fleischman MW, Reicher S, Eysselein VE and Hou LA performed the procedures; Hou LA conceived and designed the study and supervised the entire project.
Institutional review board statement: The study was reviewed and approved by the John F. Wolf, M.D. Human Subjects Committee of the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center.
Informed consent statement: Following review by the John F. Wolf, M.D. Human Subjects Committee of the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, the project was granted a waiver of the requirement for individual authorization for use and disclosure of protected health information.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Timothy Yoo, MD, Doctor, Department of Internal Medicine, Harbor-UCLA Medical Center, 1000 W. Carson St, Box 400, Torrance, CA 90509, United States. tyoo2@dhs.lacounty.gov
Telephone: +1-310-2222401 Fax: +1-310-3209688
Received: May 20, 2019
Peer-review started: May 20, 2019
First decision: August 2, 2019
Revised: August 14, 2019
Accepted: October 15, 2019
Article in press: October 15, 2019
Published online: November 16, 2019
Core Tip

Core tip: We performed a retrospective review of all patients with hepatic cirrhosis who underwent interventional endoscopic retrograde cholangiopancreatography/ endoscopic ultrasound procedures over a 3 years span at our safety-net hospital and evaluated outcomes within a 30-d period. 77 cases were included. Both Model for End-stage Liver Disease (MELD-Na) score and Child-Pugh class C predicted adverse events (P < 0.01). When MELD-Na scores were added as predictors with the effect of Child-Pugh class C, only MELD-Na scores were a significant predictor of adverse events (P < 0.01). Our data demonstrates a correlation between cirrhosis severity and adverse events and suggests that MELD-Na score may be useful in assessing procedural risk.